<DOC>
	<DOCNO>NCT01481701</DOCNO>
	<brief_summary>This Phase II study recurrent ovarian carcinoma platinum-sensitive resistant tumor Folfox regimen .</brief_summary>
	<brief_title>A Trial Evaluating Efficacy Safety Oxaliplatin With 5-Fluorouracil Patients With Recurrent Ovarian Carcinoma</brief_title>
	<detailed_description>Evaluation safety efficacy combination oxaliplatin 5FU ( Folfox ) patient ovarian carcinoma relapse either platinum-combined regimen . The Folfox regimen administer every 14 day . Evaluation toxicity perform cycle evaluation efficacy every 4 cycle chemotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>ovarian carcinoma relapse neurotoxicity grade III renal clearance &lt; 60 ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ovarian carcinoma</keyword>
	<keyword>Bordet</keyword>
	<keyword>relapse</keyword>
</DOC>